Magnesium-Diapsoral 4mmol (Magnesium Sulfate Heptahydrate)

Magnesium sulfate supplies magnesium ions that act as a calcium antagonist, stabilising neuronal and cardiac membranes, reducing neuromuscular excitability, and supporting ATP‑dependent enzymatic processes. These actions help normalize electrolyte balance, lower seizure risk, and stabilize cardiac rhythm.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and serum magnesium levels. Healthcare professionals should follow local guidelines and adjust dosing as needed.

Magnesium sulfate is commonly used in pregnancy for preeclampsia and eclampsia management, but the decision to use it should be made by a qualified obstetrician who weighs maternal benefits against potential fetal risks. Limited data are available for breastfeeding, so clinicians should consider the risk‑benefit profile.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Magnesium-Diapsoral 4mmol delivers magnesium sulfate heptahydrate in a standardized 4mmol concentration, suitable for both IV and IM routes. Compared with oral magnesium salts, it offers rapid serum level correction and precise dosing, which is essential in acute settings such as severe hypomagnesemia or obstetric emergencies.

The product should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. Before administration, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

Magnesium-Diapsoral is administered by a qualified healthcare professional either intravenously as a slow infusion or intramuscularly as a deep injection, following aseptic technique. The infusion rate and volume are adjusted according to the clinical indication and patient monitoring parameters.

Serious risks include hypermagnesemia, which can cause respiratory depression, cardiac arrest, severe hypotension, and neuromuscular blockade. Patients with renal failure or those receiving other magnesium‑containing agents are at higher risk and require close monitoring of serum magnesium levels.

Magnesium-Diapsoral should be avoided in patients with known hypersensitivity to magnesium sulfate, severe renal impairment without appropriate monitoring, and in those with existing hypermagnesemia. Caution is also advised for individuals on concurrent neuromuscular blockers or high‑dose calcium channel blockers.